Dermytol, A Novel Compound For The Prevention Of Melanoma Skin Cancer Tested For Efficacy In Mice

A novel proprietary compound, trade named Dermytol™ has been shown to reduce melanoma tumor cell growth in male mice. Six Male C57BL mice (3–4 weeks old) were treated by oral gavage with 6.0% Dermytol™ w/v 0.2ml Canola oil. Mice in a control group were administered Canola oil. In a second treatment group of 6 male C57BL mice, a topical application of 6.0% Dermytol™ w/v in a cream base was applied to a shaved 1cm 2 area of the right hind flank. Control group mice for this treatment received an application of a placebo cream base. Both treatments were applied for 7 consecutive days followed by subcutaneous injection in the right hind flank of B16‐F1 malignant melanoma tumor cells (2.0x10 5 ) in 100μl saline. Oral and topical Dermytol™ treatments were continued for 25 days after tumor cell injection. Results showed that orally treated mice showed an average decrease in tumor volume of 44.5%. Tumor volume was decreased by 61.2% in topically treated mice. This pronounced decrease in tumor volume for both applications indicates that Dermytol™ is effective at inhibiting the proliferation of B16‐F1 melanoma tumor cells and that a topical application of the compound produces a more potent effect. Source: KGK Synergize, Inc.